Skip to content

Pacific Biosciences of California

US · PACB #3373 by market cap
1.63 -0.13 -7.39%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:52

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 13 in the most recent period (2026/Q3).
  • Total institutional ownership rose 17.1 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
80.10% +17.09pp
Institutions
247 -13
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund54.91%
Public Company12.39%
Hedge Fund9.41%
Private Company2.38%
Individual/Insider1.01%
VC/PE Fund0.53%
Insurance Company0.31%
Other18.90%

Top holders as of 2026-10-31

T. Rowe Price Group, Inc. 10.69% · 33.45M sh
BlackRock 10.48% · 32.80M sh
ARK Investment Management LLC 9.51% · 29.75M sh
SoftBank Group Corp. 6.54% · 20.45M sh
The Goldman Sachs Group, Inc. 4.52% · 14.14M sh
Vanguard Capital Management, LLC 4.23% · 13.24M sh
Goldman Sachs Asset Management, L.P. 3.00% · 9.38M sh
Amova Asset Management 1.59% · 4.96M sh
Geode Capital Management, LLC 2.12% · 6.63M sh
State Street Global Advisors 1.93% · 6.05M sh
Point72 Asset Management, L.P. 1.54% · 4.79M sh
D. E. Shaw & Co., L.P. 1.35% · 4.21M sh
Two Sigma Investments, LP 1.36% · 4.24M sh
Sumitomo Mitsui Trust Asset Management 1.59% · 4.96M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 35 buys · 14 sells

NameRoleStake
Christian O. Henry Senior Business Advisor & Director 0.40%
Mark Van Oene CEO, President, Director & Interim CFO 0.32%
Kathy Ordonez Independent Director 0.13%
James Gibson Chief Financial Officer 0.05%
John Milligan Independent Chairperson 0.04%
Marshall Mohr Independent Director 0.04%
Michele Farmer Former Vice President 0.03%
William Ericson Independent Director 0.01%
Hannah Valantine Independent Director 0.01%
Randall Livingston Independent Director 0.01%
Lucy Shapiro Former Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-02 William Meyer Chief Accounting Officer Initial Statement of Beneficial 0 --
2026-10-05 James Gibson Advisor Automatic Disposition -161,815 $3.11
2026-10-05 James Gibson Advisor Derivative Exercise and Sale -500,000 $1.18–3.11
2026-08-16 Mark Van Oene CEO, President, Director & Interim CFO Open Market Disposition -26,911 $1.13
2026-08-09 Mark Van Oene CEO, President, Director & Interim CFO Other Acquisition +489,130 --
2026-08-09 Mark Van Oene CEO, President, Director & Interim CFO Other Derivative Acquisition +1,967,888 $1.15
2026-06-02 William Ericson Independent Director Other Derivative Acquisition +223,492 $1.58
2026-06-02 Kathy Ordonez Independent Director Other Derivative Acquisition +223,492 $1.58
2026-06-02 John Milligan Independent Chairperson Other Derivative Acquisition +223,492 $1.58
2026-06-02 Marshall Mohr Independent Director Other Derivative Acquisition +223,492 $1.58
2026-06-02 Christopher Smith Former Independent Director Other Derivative Acquisition +223,492 $1.58
2026-06-02 Randall Livingston Independent Director Other Derivative Acquisition +223,492 $1.58
2026-06-02 Christopher Gibson Independent Director Other Derivative Acquisition +74,497 $1.58
2026-06-02 Hannah Valantine Independent Director Other Derivative Acquisition +223,492 $1.58
2026-04-07 Christopher Gibson Independent Director Other Acquisition +57,473 --
2026-04-07 Christopher Gibson Independent Director Other Derivative Acquisition +77,842 $1.52
2026-03-31 James Gibson Advisor Open Market Disposition -88,185 $1.37
2026-03-02 Christian O. Henry Senior Business Advisor & Director Open Market Disposition -12,497 $1.51
2026-03-02 Christopher Gibson Independent Director Other Acquisition +53,913 --
2026-03-02 Christopher Gibson Independent Director Other Derivative Acquisition +73,087 $1.52

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:52:58 · For reference only, not investment advice and not tailored to your situation.

Pacific Biosciences of California discussion 0 comments

Add a comment